Mitral valve repair or replacement

Mitral valve repair or replacement

Anesthesia type	General
Airway	ETT
Lines and access	PIV, Arterial line, Central line, +/- PA catheter
Monitors	Standard ASA, arterial line BP, CVP +/- PAP, TEE, NIRS
Primary anesthetic considerations
Preoperative	-Severity and mechanism of lesion (MS vs MR, primary vs secondary) -LV size and systolic function -Pulmonary HTN, RV function -Chronic atrial fibrillation -Thromboembolism risk (LA thrombus) -Concomitant procedures (CABG, MAZE, multi valves)
Intraoperative	-Hemodynamic goals (MS vs MR) -Full heparinization before CPB -Myocardial protection and de-airing -Conduction disturbances -Weaning from CPB: LV/RV function, valve seating, gradients
Postoperative	-RV failure -SAM -Atrial fibrillation -Low cardiac output syndrome -Bleeding
Article quality
Editor rating	Unrated
User likes	0

Mitral valve repair or replacement is performed for severe mitral regurgitation (MR), mitral stenosis (MS), or mixed disease. Repair is preferred when possible because it preserves annular-ventricular continuity, maintains LV geometry, improves long-term survival, and avoids prosthetic complications. Replacement (SMVR) is performed when repair is not durable or technically feasible (severe calcifications, rheumatic disease, extensive endocarditis).

Overview

Indications

• Symptomatic severe primary (degenerative) MR
• Symptomatic severe MS
• Severe secondary (functional) MR with persistent symptoms despite GDMT
• Severe MR with LV dilation or LV dysfunction
• Recurrent MR after primary repair
• Endocarditis with structural destruction
• Concomitant need during CABG or other valve surgery

Unlike Transcatheter mitral valve repair/replacement, SMVR allows:

• Complete annular debridement
• Abscess debridement
• Annular enlargement
• Leaflet resection and chordal reconstruction
• Preservation of subvalvular apparatus
• Concomitant procedures like MAZE, left atrial appendage excision, tricuspid repair, or CABG
• Durability advantage in primary MR in low risk patients

Transcatheter mitral valve repair/replacement (TMVR) is preferred in:

• Elderly patients
• High or prohibitive surgical risk
• Frailty or hostile chest

Surgical procedure

Most commonly performed via median sternotomy, but minimally invasive approaches exists.

After systemic heparinization (ACT > 480 seconds), cardiopulmonary bypass is established with aortic and right atrial (or bicaval) cannulation. Aortic cross-clamp is applied, and myocardial protection is achieved through cold blood cardioplegia delivered either through aortic root (antegrade) and/or coronary sinus (retrograde).

Left atriotomy (via interatrial groove or transseptal approach) is performed and mitral valve is directly inspected to determine mechanism of pathology.

Repair techniques include annuloplasty ring placement, leaflet resection, chordal replacement, or commissurotomy (MS).

Replacement involves native valve excision (preserving posterior leaflet, if possible, to maintain ventricular geometry). Mechanical or bioprosthetic valve is then implanted. Sutures are placed circumferentially around the annulus. Preservation of subvalvular apparatus reduces postoperative LV dysfunction.

Concomitant MAZE procedure frequently performed in patients with chronic atrial fibrillation and involves surgical ablation lines created in atria. This can be combined with left atrial appendage ligation or excision.

De-airing is critical due to open left atrium and TEE guidance before cross-clamp removal. After reperfusion and rewarming, patient is weaned from CPB.

Temporary epicardial pacing wires are routinely placed due to risk of conduction disturbances. After protamine administration and hemostasis, chest closure is performed.

Preoperative management

Patient evaluation

System	Considerations
Airway	-Prior sternotomy may limit neck mobility
Neurologic	-History of stroke, TIA, cognitive baseline
Cardiovascular	-Severity assessment (MS vs MR) -LV size and systolic function -LA size -RV function -Pulmonary HTN (RV risk post bypass) -CAD (concomitant CABG) -Rhythm (atrial fibrillation)
Pulmonary	-Restrictive lung physiology (HF/sternotomy) -COPD (prolonged vent weaning)
Gastrointestinal	-Dysphagia, esophageal/GI tract surgeries (TEE)
Hematologic	-Anticoagulation use, blood products available
Renal	-Baseline Cr, kidney disease (CPB AKI risk)
Endocrine	-DM
Other	-Endocarditis (longer CPB)

Echocardiography

Severe Mitral Stenosis - Valve area < 1.0 cm2, mean gradient > 10mmHg, PAP > 50mmHg

Severe Mitral Regurgitation - EROA > 0.4cm2, regurgitant volume > 60mL, regurgitant fraction > 50%, vena contracta > 7mm

Labs and studies

• CBC, CMP, PT/PTT
• T&C pRBC FFP
• TTE/TEE, cardiac cath, EKG, CXR

Operating room setup

• Have at least 5-8 channels for infusions
  • Epinephrine, norepinephrine, carrier, insulin (some institutions use phenylephrine in place of norepi)
  • Consider TXA, ketamine, dexmedetomidine, cefazolin
• Drugs:
  • Emergency medications (bolus):
    • epinephrine, atropine
    • Other bolus vasopressors (e.g. vasopressin, phenylephrine, norepinephrine)
    • +/- esmolol, nicardipine, and nitroprusside
  • Heparin, protamine, calcium
  • +/- Magnesium
• Perfusion technician should be available along with cell saver
• Fluid warmer
• Triple transducers primed and zeroed
• Internal defibrillator/pacer available in room
• TEE machine with appropriately sized probe

Patient preparation and premedication

• Continue beta blockers, statins, antianginals
• Hold ACE inhibitors/ARBs and DOACs per protocol

Regional and neuraxial techniques

• Pre-Op: Erector Spinae Plane Block
• Intra-op: Parasternal Intercostal Block - after sternal wound closure and prior to emergence

Procedure variants

	Variant 1	Variant 2
Unique considerations
Indications
Position
Surgical time
EBL
Postoperative disposition
Pain management
Potential complications